The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isAlso approved for lymphangioleiomyomatosis and used on drug-eluting coronary stents.
- What to watchPersistent fever, cough or infection.
How Rapamycin works
Rapamycin is not an mTOR inhibitor in the way that phrase implies. It is an allosteric inhibitor of ONE of the two complexes mTOR forms, and the entire longevity protocol is an attempt to keep it that way.
mTORC2 is a different complex with a different partner protein, RICTOR, and rapamycin does not bind it acutely. With prolonged exposure, however, newly synthesized mTOR is captured by FKBP12-rapamycin before it can assemble into mTORC2, so mTORC2 is gradually depleted in a cell-type- and duration-dependent way Ballesteros-Álvarez 2021. mTORC2 is the complex that phosphorylates AKT at serine 473 and carries insulin signaling. They are a DURATION effect, and duration is the variable a weekly schedule controls.
- Oral
Research on Rapamycin7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA-approved (transplant); longevity off-label.
Human clinical evidence
FDA-approved since 1999 as sirolimus, for prevention of kidney transplant rejection. Also approved for lymphangioleiomyomatosis and used on drug-eluting coronary stents.
The longevity use is off-label and not proven in humans. The strongest human hint is a Novartis trial of the rapalog everolimus in adults over 65, which reported improved influenza vaccine response — an immune-ageing endpoint rather than a lifespan one. Trials in dogs (the Dog Aging Project) and human pilots are ongoing.
Correlative data
The most-replicated lifespan result in mammalian biology — the NIA Interventions Testing Program extended median lifespan in mice across multiple independent sites, including when started in old age.
That separation is a hypothesis, not a demonstrated fact.
How the mechanism reads
Inhibits mTORC1 by binding FKBP12. mTOR is the cell's nutrient sensor: when it is active, the cell builds; when it is inhibited, the cell switches to autophagy — recycling damaged proteins and organelles. Accumulated cellular damage is a central ageing mechanism, so this is the most mechanistically coherent longevity target that exists.
MechanisticThe predicted downsides come from the same mechanism. Suppressing building means suppressing immune cell proliferation, wound healing and muscle protein synthesis.
MechanisticWhich drives the insulin resistance seen in transplant patients. And the whole uncertainty rests on nobody having proven it does.
Mechanistic
Sources
- Moel M, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025 · PMID 40188830
- Harinath G, et al. GeroScience 2025 · PMID 39873920
- Arriola Apelo SI, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell 2016 · PMID 26463117
- Baghdadi M, et al. Intermittent rapamycin feeding recapitulates some effects of continuous treatment while maintaining lifespan extension. Molecular Metabolism 2024 · PMID 38360109
- Singh R, et al. Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice. Journals of Gerontology Series A 2026 · PMID 41863332
- Ballesteros-Álvarez J, et al. mTORC2: The other mTOR in autophagy regulation. Aging Cell 2021 · PMID 34250734
Rapamycin safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active infection or poor wound healing: mTOR inhibition suppresses immune cells and tissue repair.
- Planned surgery within weeks.
- Strong CYP3A4 inhibitors or grapefruit: they raise rapamycin levels sharply.
- Pregnancy or conception plans: mTOR inhibition lowers sperm output and affects fetal growth.
- Uncontrolled high lipids or diabetes: mTORC1 inhibition worsens both.
What’s expected
- Mouth sores in some users.
- Higher triglycerides and cholesterol, and a mild rise in fasting glucose.
- Slower wound healing.
- A slightly muted immune response.
Watch for
- Persistent fever, cough or infection.
- Dry cough with breathlessness: possible pneumonitis.
- Leg swelling or protein in urine.
- Mouth ulcers that do not heal.
Labs that tell you it’s working
- Sirolimus, Whole Blood
- Lipid Panel
- HbA1c (Hemoglobin A1c)
- Complete Blood Count (CBC) w/ Differential
Rapamycin (sirolimus) inhibits mTORC1; lipid, glucose, blood count and drug-level labs follow, and the whole-blood level shows exposure directly. PMID 40188830 PMID 40778880
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Rapamycin FAQ4 common questions
- Is Rapamycin approved for human use?
- Rapamycin is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Rapamycin researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Sirolimus, Whole Blood; Lipid Panel; HbA1c; Complete Blood Count: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Rapamycin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



